1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR

CXCR

CXC chemokine receptors; C-X-C motif chemokine receptors

CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4846
    Ac-Pro-Gly-Pro-OH
    Agonist 99.49%
    Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as CXCR2 agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis.
    Ac-Pro-Gly-Pro-OH
  • HY-117971
    BVT173187
    99.97%
    BVT173187 is a selective inhibitor of the neutrophil formyl peptide receptor FPR1, with activity that inhibits FPR1 activation. BVT173187 inhibits FPR1 agonist-induced activation in neutrophils, reduces adhesion molecule mobilization and superoxide anion production, and has inhibitory activity on FPR1 similar to that of earlier described peptide antagonists, but also has effects on C5aR and CXCR signaling.
    BVT173187
  • HY-139873
    CXCR2 antagonist 2
    Antagonist 99.32%
    CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunoresearch with an IC50 value of 95 nM.
    CXCR2 antagonist 2
  • HY-P990313
    ABX-IL8
    98.70%
    ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    ABX-IL8
  • HY-110099
    (±)-NBI-74330
    Antagonist 99.12%
    (±)-NBI-74330 is a potent and selective CXCR3 antagonist. (±)-NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±)-NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model.
    (±)-NBI-74330
  • HY-P990737
    Eltrekibart
    98.00%
    Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Eltrekibart
  • HY-RS03400
    CXCR2 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR2 Human Pre-designed siRNA Set A
  • HY-18263A
    Elubrixin
    Antagonist
    Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin
  • HY-120878A
    (R,R)-CXCR2-IN-2
    Antagonist 99.37%
    (R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant CXCR2 antagonist with a pIC50 of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively.
    (R,R)-CXCR2-IN-2
  • HY-101458
    IT1t
    Antagonist
    IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.
    IT1t
  • HY-103009
    MSX-127
    Antagonist 99.68%
    MSX-127 is a CXCR4 antagonist. MSX-127 inhibits cancer metastasis.
    MSX-127
  • HY-P4111
    Peptide R
    Antagonist
    Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research.
    Peptide R
  • HY-13021
    SRT3190
    Antagonist 99.77%
    SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.
    SRT3190
  • HY-P4111A
    Peptide R TFA
    Antagonist 98.34%
    Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research.
    Peptide R TFA
  • HY-162632
    Hit 14
    Inhibitor ≥99.0%
    Hit 14 is an inhibitor for C-X-C chemokine receptor type 4 (CXCR4) with IC50 of 254 nM. Hit 14 inhibits the migration and invasion of cell MDA-MB-231. Hit 14 inhibits the Akt phosphorylation, exhibits anti-inflammatory activity, and ameliorateds the ear swelling and damage in mouse models.
    Hit 14
  • HY-P7061
    ALX 40-4C
    Inhibitor
    ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
    ALX 40-4C
  • HY-10011A
    (S)-SCH 563705
    Antagonist 99.94%
    (S)-SCH 563705 is a S-enantiomer of SCH 563705. SCH 563705 (compound 16) is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.
    (S)-SCH 563705
  • HY-111149
    PS372424
    Agonist
    PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation.
    PS372424
  • HY-P4109A
    vMIP-II (1-21) TFA
    Inhibitor
    vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM).
    vMIP-II (1-21) TFA
  • HY-RS03403
    CXCR3 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR3 Human Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.